Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dexpramipexole

Biogen Idec building

Biogen wins European spinal muscular atrophy first

Spinraza wins accelerated approval to treat patients with the most common form of SMA

- PMLiVE

Biogen spin-out makes first acquisition

Bioverativ attains rare disease group True North

Biogen Idec building

Biogen hands out $120m upfront for Remedy stroke drug

Cirara vying to be first new treatment since the 1990s

- PMLiVE

FDA clears new ALS drug Radicava ahead of schedule

MT Pharma’s medicine will soon offer US patients an alternative to Sanofi’s Rilutek

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

- PMLiVE

AB Science claims first with motor neurone disease therapy

ALS patients on masitnib lived longer without their disease progressing

Biogen Idec building

NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta

Recommends the treatment after new cost effectiveness and a discount provided

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

Biogen Idec building

Biogen completes haemophilia business separation

Spin-out Bioverativ launched to focus exclusively on rare blood disorders

Biogen Idec building

Biogen proffers new data to support high-priced Spinraza

Trial demonstrates statistically-significant risk reduction in paediatric SMA for potential blockbuster drug

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links